"Study Clarifies Semaglutide's Impact on Mental Health and Side Effects"
A new NIH study has found that the diabetes and weight loss drugs Ozempic and Wegovy, which contain semaglutide, do not increase the risk of suicidal thoughts compared to other weight loss medications. The study analyzed health records of patients with obesity or overweight and found a lower risk of first-time or recurring suicidal ideation in those taking semaglutide. This research comes after concerns were raised by anecdotal reports and regulatory reviews in Europe and the U.S. Despite the safety findings, access to these drugs remains limited due to high costs and supply shortages.
